Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
41.25
+2.29 (5.88%)
May 29, 2026, 3:10 PM CST
SHE:300255 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | -355.81 | -357.9 | -249.48 | -1,240 | 17.51 | 233.57 |
Depreciation & Amortization | 69.55 | 69.55 | 73.7 | 74.7 | 56.94 | 55.8 |
Other Amortization | 2.21 | 2.21 | 1.05 | 0.8 | 0.62 | - |
Loss (Gain) From Sale of Assets | 0.23 | 0.23 | 0.78 | 0 | 0.01 | - |
Asset Writedown & Restructuring Costs | 3.68 | 3.68 | 1.3 | 1.78 | 2.12 | 0.11 |
Loss (Gain) From Sale of Investments | -1.67 | -1.67 | -33.26 | -0.01 | - | - |
Provision & Write-off of Bad Debts | 29.53 | 29.53 | 6.61 | 15.38 | 6.51 | -0.13 |
Other Operating Activities | 133.79 | 218.66 | 169.76 | 730.56 | 98.1 | 62.96 |
Change in Accounts Receivable | 12.29 | 12.29 | -21.01 | 284.66 | -97.06 | 91.52 |
Change in Inventory | 44.36 | 44.36 | 190 | 161.28 | -156.01 | -398.02 |
Change in Accounts Payable | 32.32 | 32.32 | -82.25 | 13.82 | 72.17 | -48.54 |
Operating Cash Flow | -27.1 | 55.68 | 56.22 | 33.73 | 3.13 | 2.87 |
Operating Cash Flow Growth | - | -0.95% | 66.69% | 979.06% | 8.85% | - |
Capital Expenditures | -123.85 | -123.36 | -239.59 | -239.32 | -431.22 | -308.08 |
Sale of Property, Plant & Equipment | - | - | 0.06 | 0.02 | 0 | - |
Investment in Securities | - | - | - | 0 | - | - |
Other Investing Activities | 0.2 | -0 | 5.77 | 0.45 | -0.1 | 0.78 |
Investing Cash Flow | -123.6 | -123.31 | -233.76 | -238.85 | -431.32 | -307.31 |
Long-Term Debt Issued | - | 2,201 | 2,000 | 1,346 | 2,816 | 1,581 |
Total Debt Issued | 2,782 | 2,201 | 2,000 | 1,346 | 2,816 | 1,581 |
Long-Term Debt Repaid | - | -2,242 | -1,687 | -1,529 | -2,030 | -1,182 |
Total Debt Repaid | -2,700 | -2,242 | -1,687 | -1,529 | -2,030 | -1,182 |
Net Debt Issued (Repaid) | 82.22 | -41.31 | 312.96 | -182.36 | 786.08 | 399.46 |
Common Dividends Paid | -118 | -118.69 | -119.93 | -107.73 | -124 | -61.89 |
Other Financing Activities | 74.45 | 101.46 | -11.3 | -4.85 | -8.63 | 5.39 |
Financing Cash Flow | 38.66 | -58.54 | 181.73 | -294.94 | 653.44 | 342.96 |
Foreign Exchange Rate Adjustments | 0.38 | 2.28 | 0.84 | 3.03 | 12.96 | -3.49 |
Net Cash Flow | -111.66 | -123.89 | 5.03 | -497.03 | 238.2 | 35.04 |
Free Cash Flow | -150.95 | -67.68 | -183.37 | -205.6 | -428.1 | -305.21 |
Free Cash Flow Margin | -17.30% | -7.73% | -17.79% | -14.58% | -18.32% | -10.28% |
Free Cash Flow Per Share | -0.17 | -0.07 | -0.20 | -0.22 | -0.49 | -0.33 |
Cash Income Tax Paid | 33.47 | 28.98 | 22.83 | 149.83 | 70.81 | 163.73 |
Levered Free Cash Flow | 332.49 | 82.38 | -43.88 | 55.71 | -500.03 | -469.98 |
Unlevered Free Cash Flow | 393.37 | 142.95 | 20.39 | 115.97 | -441.88 | -431.04 |
Change in Working Capital | 91.39 | 91.39 | 85.78 | 450.73 | -178.69 | -349.44 |